Abstract:Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces cell death in various types of cancer cells but has little or no effects on normal cells. Unfortunately, not all cancer cells respond to TRAIL; therefore, TRAIL sensitizing agents are currently being explored. Here, we reported that 6-(4-N,N-Dimethylaminophenyltelluro)-6-deoxy-β-cyclodextrin (DTCD), a cyclodextrin-derived diorganyl telluride which has been identified as an excellent inhibitor of thioredoxin reductase (TrxR), could sensitize TRAIL resistant human ovarian cancer cells to undergo apoptosis. In vitro, DTCD enhanced TRAIL-induced cytotoxicity in human ovarian cancer cells through up-regulation of DR5. Luciferase analysis and CHIP assays showed that DTCD increased DR5 promoter activity via Sp1 activation. Additionally, DTCD stimulated extracellular signal-regulated kinase (ERK) activation, while the ERK inhibitor PD98059 blocked DTCD-induced DR5 expression and suppressed binding of Sp1 to the DR5 promoter. We further demonstrated that DTCD could induce the release of ASK1 from its complex with Trx-1, and recovered its kinase activity. Meanwhile, suppression of ASK1 by RNA interference led to decreased ERK phosphorylation induced by DTCD. The underlying mechanisms reveal that Trx-1 is heavily oxidized in response to DTCD treatment, in accordance with the fact that DTCD could inhibit the activity of TrxR that reduces oxidized Trx-1. Moreover, using an A2780 xenograft model, DTCD plus TRAIL significantly inhibited the growth of tumor in vivo. Our results suggest that Trx/TrxR system inhibition may play a critical role in apoptosis by combined treatment with DTCD and TRAIL, and raise the possibility that their combination may be a promising strategy for ovarian carcinoma treatment.

The research about the relationship between Trx system and tumor cell apoptosis as well as immune microenvironment

TRAIL and Cancer Therapy

Interplay Between Apoptosis and Autophagy in Colorectal Cancer

Targeting the Thioredoxin System for Cancer Therapy.

Overview of thioredoxin system and targeted therapies for acute leukemia

Inhibiting TrxR Suppresses Liver Cancer by Inducing Apoptosis and Eliciting Potent Antitumor Immunity

Thioredoxin and neoplasm metastasis

Thioredoxin Activity Confers Resistance Against Oxidative Stress In Tumor-Infiltrating Nk Cells

Thioredoxin Signaling Pathways in Cancer

Research Progress on Mitochondria Regulating Tumor Immunity.

Thioredoxin Induces Tregs To Generate An Immunotolerant Tumor Microenvironment In Metastatic Melanoma

Exploring the Thioredoxin System as a Therapeutic Target in Cancer: Mechanisms and Implications

Expression and Clinical Significance of Thioredoxin-1 in Pancreatic Cancer

Research progress of thioredoxin system

Relationship between thioredoxin system and tumors

Multifaceted role of redox pattern in the tumor immune microenvironment regarding autophagy and apoptosis

Inhibition of TrxR2 suppressed NSCLC cell proliferation, metabolism and induced cell apoptosis through decreasing antioxidant activity.

Research Progress on the Role of Regulatory T Cell in Tumor Microenvironment in the Treatment of Breast Cancer

Novel Insights into the Synergistic Interaction of a Thioredoxin Reductase Inhibitor and TRAIL: the Activation of the ASK1-ERK-Sp1 Pathway

Research Progress of TXNIP as a Tumor Suppressor Gene Participating in the Metabolic Reprogramming and Oxidative Stress of Cancer Cells in Various Cancers

Significance of the mitochondrial thioredoxin reductase in cancer cells: An update on role, targets and inhibitors